Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age 1 2 and time period and are affected by the pandemic 3 Fredrik Nyberg 1; Magnus Lindh 2,3; Lowie E.G.W. Vanfleteren 4,5; Niklas Hammar 6; Björn 4 Wettermark 7; Johan Sundström 8,9; Ailiana Santosa 1; Brian K. Kirui 1; Magnus Gisslén 2,10 5 1. School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 6

7 2. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of 8 Gothenburg, Gothenburg, Sweden

- 9 3. Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden
- 10 4. COPD Center, Department of Respiratory Medicine and Allergology, Sahlgrenska University 11 Hospital, Gothenburg, Sweden
- 12 5. Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska
- Academy, University of Gothenburg, Gothenburg, Sweden 13

14 6. Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institute, Stockholm, 15 Sweden

- 16 7. Pharmacoepidemiology & Social Pharmacy, Department of Pharmacy, Uppsala University, 17 Uppsala, Sweden
- 8. Clinical Epidemiology Unit, Department of Medical Sciences, Uppsala University, Uppsala, Sweden 18
- 19 9. The George Institute for Global Health, University of New South Wales, Sydney, Australia
- 20 10. Region Västra Götaland, Department of Infectious Diseases, Sahlgrenska University Hospital, 21 Gothenburg, Sweden
- 22
- 23 Corresponding author:
- 24 Fredrik Nyberg, MPH MD PhD FISPE
- 25 **Professor of Register Epidemiology**
- 26 School of Public Health and Community Medicine,
- 27 Institute of Medicine, Sahlgrenska Academy, University of Gothenburg
- 28 Box 463, 405 30 Gothenburg, Sweden
- 29 Visiting address: Medicinaregatan 18A, Gothenburg
- 30 Email: Fredrik.Nyberg.2@gu.se
- 31 Tel: +46 31 7866289, Mobile: +46 76 6186289
- 32 NOTE: This preprint reports new research that has not been certified by peer review and should not
- be used to guide clinical practice. 33
- 34

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

35 Abstract

- 36 Background
- 37 With large-scale COVID-19 vaccination implemented world-wide, safety signals needing rapid
- 38 evaluation will emerge. We report population-based, age- and-sex-specific background incidence
- 39 rates of conditions representing potential vaccine adverse events of special interest (AESI) for the
- 40 Swedish general population using register data.
- 41 Methods
- 42 We studied an age/sex-stratified random 10% sample of the Swedish population on 1 Jan 2020,
- 43 followed for AESI outcomes during 1 year, as the COVID-19 pandemic emerged and developed,
- 44 before the start of vaccinations. We selected and defined the following outcomes based on
- 45 information from regulatory authorities, large-scale adverse events initiatives and previous studies:
- 46 aseptic meningitis, febrile seizure, Kawasaki syndrome, MISC, post-infectious arthritis, arthritis,
- 47 myocarditis, ARDS, myocardial infarction, stroke, ischemic stroke, hemorrhagic stroke, venous
- 48 thromboembolism, pulmonary embolism, kidney failure, liver failure, erythema multiforme,
- 49 disseminated intravascular coagulation, autoimmune thyroiditis, and appendicitis. We calculated
- 50 incidence rates stratified by age, sex and time period (quarters of 2020), and classified them using
- 51 Council of International Organizations of Medical Sciences (CIOMS) categories: very common,
- 52 common, uncommon, rare, or very rare.
- 53 Results
- 54 We included 972,723 study subjects, representing the Swedish national population on 1 Jan 2020.
- 55 We found that AESI incidence rates vary greatly by age and in some cases sex. Several common AESIs
- showed expected increase with age, while some (e.g. appendicitis, aseptic meningitis, autoimmune
- 57 thyroiditis, Kawasaki syndrome and MISC) were more common in young people, and others
- exhibited a flatter age pattern (e.g. myocarditis, DIC and erythema multiforme). Consequently, the
- 59 CIOMS classification for AESIs varied widely according to age. Considerable variability was suggested
- 60 for some AESI rates across the 4 quarters of 2020, potentially related to pandemic waves, seasonal
- 61 variation, healthcare system overload or other healthcare delivery effects.
- 62 Conclusion
- Age, sex, and timing of rates are important to consider when background AESI rates are compared to
 corresponding rates observed with COVID-19 vaccines.
- 65

medRxiv preprint doi: https://doi.org/10.1101/2021.10.04.21263507; this version posted October 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

66 Main text

67

68 Introduction

69 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged in Wuhan in 70 December 2019 (1), causing the enigmatic disease subsequently named Coronavirus disease 2019 71 (COVID-19). During 2020, the disease developed into a large-scale pandemic, spreading to most 72 countries in the world, including entering second, third or even fourth wave in many places, with 73 cumulative numbers of over 83 million cases and 1.8 million deaths reported globally during the first 74 year until end of 2020 (2). By the end of 2020, vaccines had been developed and vaccination 75 campaigns were initiated in multiple countries, including Sweden. The first COVID-19 case in Sweden 76 was reported on 31 January 2020, and in parallel with Europe becoming the epicenter for the 77 epidemic during the Spring of 2020, the disease rapidly expanded in Sweden, causing severe strain 78 on society and the healthcare system (3, 4). At the peak of the second big wave of infections, 79 vaccination was initiated in the elderly population just before the end of 2020, and has continued at 80 pace during 2021, reaching successively larger sections of the population and younger population 81 groups. 82 With the initiation of vaccination against COVID-19 in Sweden and across the world by end of 2020, 83 regulatory agencies, pharmaceutical companies, academia and other stakeholders are developing 84 safety surveillance strategies, largely based on observational data. In Europe, for instance, the 85 vACCine covid-19 monitoring readinESS (ACCESS) project funded by the European Medicines Agency 86 includes a protocol to assess background rates of conditions considered to represent potential 87 Adverse Events of Special Interest (AESI) from observational data (5). Similarly, The US FDA Center 88 for Biologics Evaluation and Research have published a protocol on "Background Rates of Adverse 89 Events of Special Interest for COVID-19 Vaccine Safety Monitoring" (6). Local background rates are 90 generally considered most appropriate for obvious reasons (7), but expected rates can also be better

- 91 informed by availability of background rates from many different populations, time periods and
- 92 areas, to understand variability and consistency of rates. Data on background rates of AESI for
- 93 COVID-19 vaccines from some different areas have started to appear in the scientific literature, for 94
- example a multi-database study by the Observational Health Data Sciences and Informatics (OHDSI) 95 community (8). These efforts are important, as a comprehensive and thorough monitoring of vaccine
- 96 safety will be an essential component in addressing public concerns about the rapid COVID-19
- 97 vaccine development and deployment, and support efforts to address vaccine hesitancy. Here, we
- 98 provide descriptive epidemiology on background rates for a range of AESI in Sweden, looking at time
- 99 periods just prior to and during the COVID-19 pandemic, and before extensive vaccination was
- 100 initiated, in order to inform surveillance efforts in Sweden and internationally.
- 101

102 Methods

103 Study design

104 Population-based cohort study to estimate incidence rates of conditions representing Adverse 105 Events of Special interest (AESI).

106 The analyses were based on the larger SCIFI-PEARL (Swedish Covid-19 Investigation for Future

107 Insights – a Population Epidemiology Approach using Register Linkage) project, which has been

108 described elsewhere (9). A subproject known as RECOVAC (Register-based large-scale national

- 4
- 109 population study to monitor Covid-19 vaccination effectiveness and safety) focuses on COVID-19
- 110 vaccination research questions and this analysis is a first component of that effort.

111 Data sources

- 112 The current analyses were based on the Swedish national population on 1 Jan 2020, before the
- 113 outbreak of the COVID-19 pandemic. The study population was identified from national registers at
- 114 Statistics Sweden, with age and sex data. To this study population we linked data from the National
- 115 Patient Register (NPR), which includes data on all hospitalizations and outpatient specialist care visits
- 116 in Sweden, including date of admission or date of visit and diagnoses coded with International
- 117 Classification of Diseases version 10 (ICD-10) codes, Swedish national version (9).

118 Study Population and study period

- 119 The study population was an age-sex stratified sample of the Swedish population as of 1 Jan 2020.
- 120 The number of individuals sampled and sampling fractions from the total population (i.e.
- 121 representing weights to obtain numbers representative for the general Swedish population) are
- 122 given in Suppl Table 1. The population was followed for 1 year from the index date of 1 Jan 2020, i.e.
- 123 during the quarter before the pandemic had spread substantially in Sweden and then during the first
- 124 3 quarters of pandemic spreading.

Outcomes 125

- 126 The investigated outcomes represent adverse events of special interest (AESIs) that have been
- 127 suggested as being particularly important to track following COVID-19 vaccination, and for which
- 128 there is a need to have solid information on background rates. The AESIs were identified from the
- "Priority list of adverse events of special interest: COVID-19" AESI list by the Brighton Collaboration 129
- 130 (10), the "Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety
- 131 Monitoring" protocol published by the FDA Center for Biologics Evaluation and Research (6), and
- 132 lists of AESI in protocols from the EMA ACCESS project (5). Algorithms defining AESIs by ICD-10 codes
- 133 were developed based on these sources, some other study protocols and proposals, and a review of
- 134 suitable codes in the Swedish national version of ICD-10. Events were identified by ICD codes from
- 135 the NPR, representing hospitalization or outpatient specialist visit for the condition. Based on the
- availability of ICD codes in our database, the following conditions could be identified with all 136
- required ICD codes that we had defined: aseptic meningitis, febrile seizure, Kawasaki syndrome, 137
- MISC, postinfectious arthritis, arthritis (broad definition), myocarditis, ARDS, myocardial infarction, 138
- 139 stroke, ischemic stroke, hemorrhagic stroke, venous thromboembolism, pulmonary embolism,
- 140 kidney failure, liver failure, erythema multiforme, disseminated intravascular coagulation,
- 141 autoimmune thyroiditis, appendicitis.
- 142 We evaluated incidence in the total population, i.e. did not require a "clean observation window" of
- 143 individuals with data indicating they were free of any earlier manifestation of each condition during
- 144 that window prior to the index start date, similar to the ACCESS protocol (5). This is also more
- 145 consistent with real-life vaccine monitoring, as AESIs for most conditions may occur or be
- 146 exacerbated in any individual, including those with earlier manifestations of the same pre-existing
- 147 condition. The full ICD-10 definitions used are provided in Suppl Table 2.

148 Analysis

- 149 The follow-up was evaluated for the full calendar year 2020, as well as for each quarter of 2020 (in
- 150 Sweden, quarter 1 was essentially pre-pandemic, quarter 2 was first wave, quarter 3 was post-wave
- 1 and quarter 4 was second wave of the pandemic; the time course of the pandemic in cases and 151

medRxiv preprint doi: https://doi.org/10.1101/2021.10.04.21263507; this version posted October 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- deaths is illustrated in Suppl Fig 1 as 7-day running average for COVID-19 cases and deaths over the
- 153 year for 2020 from our database). For each event in each time period analysis (full year or quarter),
- individuals contributed person-time of follow-up from the start of that time period until the event
- 155 occurred, end of the follow-up for that time period, or death, whichever occurred first.
- 156 We estimated incidence rates as the number of events divided by the person-time at risk (per
- 157 100,000 person-years). All estimates were weighted to the age and sex distribution of the total
- 158 Swedish population using the sampling fractions for our population as weights. Using a similar
- approach as ref 7, we also calculated age/sex-specific incidence rates, where age was stratified in
- 160 the age groups 1-5, 6-17, 18-35, 36-55, 56-64, 65-74, 75-84, and 85 years and older. All estimated
- 161 incidence rates, overall and age/sex-specific rates, were classified using the World Health
- 162 Organization Council for International Organizations of Medical Sciences (CIOMS) thresholds: very
- 163 common ($\geq 1/10$), common (< 1/10 to $\geq 1/100$), uncommon (< 1/100 to $\geq 1/1,000$), rare (< 1/1,000 to
- 164 $\geq 1/10,000$), and very rare (<1/10,000) (12).
- 165 Statistical analyses were performed using the R statistical program version 4.0.2 (13).

166 Ethical approval

- 167 The research was approved by the Swedish Ethics Review Authority, No 2020-01800, 2020-05829,
- 168 2021-00267, 2021-00829, 2021-02106.

169 *Results*

- 170 Overall, we had information on 972,723 study subjects (480,322 men and 492,401 women) who
- 171 generated 957,477 person-years of follow-up during 2020 (Table 1). The corresponding weighted
- 172 Swedish population sample is shown in Table 1. The full age and sex distribution of the study
- 173 population, as well as sampling fractions from the Swedish total population, are shown in Suppl
- 174 Table 1.
- 175 The incidence rates of each AESI, overall, by sex, and stratified by age and sex are illustrated in Table
- 176 2. Each cell is colour-coded after the CIOMS adverse event frequency system (very common,
- 177 common, uncommon, rare, or very rare).
- 178 There is substantial variation for most AESIs by age, while sex differences are more discrete for most
- 179 AESIs. The age variation is clearly seen in Figure 1, where several common conditions increase as
- 180 expected with age, but some conditions show a different pattern. Appendicitis, aseptic meningitis,
- autoimmune thyroiditis, Kawasaki syndrome and MISC are more common in children or younger
- ages. Myocarditis, DIC and erythema multiforme have a more equal distribution across ages. The
- 183 greatest sex differences were seen for myocarditis, arthritis, autoimmune thyroiditis and ARDS.
- 184 In Figure 2, the incidence trend over the four quarters of 2020 is illustrated. Some AESIs, e.g. venous
- 185 thromboembolism, hemorrhagic stroke and postinfectious arthritis exhibit a decline in incidence
- 186 during the year. Some AESIs, especially ARDS and acute liver failure follow a trend with highest
- 187 incidence in the second and fourth quarter, corresponding approximately to wave 1 and wave 2 of
- 188 the COVID-19 pandemic in Sweden. Erythema multiforme shows an inverse pattern, being lower
- during the wave 1 and 2 quarters. The MISC diagnosis was not apparent or little used before quarter
- 190 4, where the related diagnosis Kawasaki syndrome tended to decrease after an earlier increase
- 191 during the first pandemic quarter.
- 192 Discussion

medRxiv preprint doi: https://doi.org/10.1101/2021.10.04.21263507; this version posted October 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We report descriptive epidemiology for a number of AESIs of potential interest for safety follow-up 193 194 of COVID-19 vaccines, from an unselected national population. We describe baseline rates of these

- 195 AESIs during the year 2020 overall and by quarter. Our results illustrate a number of important
- 196 points for upcoming studies of vaccine safety.

197 First, the substantial variability of rates by age, and for certain outcomes also by sex, imply that it will be important to have adequate demographic comparability for vaccinated and non-vaccinated 198 199 groups that are compared, or alternatively to ensure adequate adjustment or standardization for 200 age and sex if background rates are to be used for safety surveillance. It also means that adverse 201 event rates reported without reference to age or sex distributions will be very difficult to interpret.

202 Second, the clear trends over quarters seen for some AESI during the pandemic in Sweden, with 203 variable patterns, imply that comparing rates across appropriate time periods will be crucial. For 204 example, a doubled risk of an adverse event by a vaccine during a period when in fact the 205 background rate of that event in the underlying population as measured by healthcare encounters is 206 temporarily half of what it normally is may not be detected if a comparison is made with a historical 207 or other period when the rate is at its habitual level. Similarly, for events that are increased by the 208 infectious disease itself, e.g. MISC, if these are also increased by a vaccine, this may be difficult to 209 discern unless the comparison is made during contemporaneous time periods when the disease is 210 active. Therefore, contemporaneous studies such as the current study are essential, and it will not 211 be adequate to rely on historical background rates from literature only. Further, we found 212 substantial heterogeneity across time periods *during* the early phases of the pandemic that vaccines 213 are now used to combat, suggesting that using a single overall estimate from one selected time 214 period may be inadequate to represent the true comparator event incidence. Such patterns may 215 potentially be related to COVID-19 pandemic waves (i.e. background incidence of COVID-19), 216 seasonal variations, healthcare system overload or other healthcare-related changes during a time 217 of pandemic, e.g. changes in registration or reporting of diagnoses related to the pandemic, 218 changing consultation behaviour of patients, increasing digital healthcare delivery, or other factors. 219 For example, coagulation disorders have been associated with COVID-19 (14), and potential adverse

- 220 events related to coagulation disorders have recently been linked to some COVID-19 vaccines (15-221 18). Here we report background rates for venous thromboembolism, pulmonary embolism, stroke
- 222 and ischemic stroke and DIC, conditions that are all relevant for this AESI category. It may be noted
- 223 that rates for these individual conditions have different relationships with age, as well as across the
- 224 4 quarters that we studied. Myocarditis is another condition that has recently been of interest as a 225 potential vaccine adverse event, particularly in younger males (19), and has been related to COVID-
- 19 (20). In our data, we see substantially higher background rates in men than women, and with a 226
- 227 tendency that the highest rates are observed in the 18-35 year age group, which will be important to consider when further evaluating this potential safety issue. The rate of myocarditis was also highest 228
- in the 4th quarter, during the intensive 2nd pandemic wave in Sweden, so background incidence of 229
- 230 COVID-19 over time may be quite important to consider.

231 Overall, it is comforting that despite variability and differences, our findings also show consistency 232 with prior reports from the literature on many points. Nevertheless, recent large multi-country 233 studies have shown considerable heterogeneity across populations, for example data reported from 234 the ACCESS project, which showed similar magnitudes of heterogeneity in background rates (3). The 235 pooled rates across databases from a study by the OHDSI group showed many similarities to our 236 rates for AESIs that were included in both studies; in addition, they also reported variability across 237 sites and databases (8). This further underscores that population heterogeneity needs to be taken 238 into account in the evaluation of AESIs.

7

239 Considering the large variability that was seen across age, sex, and time period, we would urge 240 caution when using external reference incidence rates to make comparisons with incidences 241 observed in vaccinated individuals, as the risk of systematic bias due to differences between 242 populations and situations may be substantial. Comparing incidence rates that originate from 243 different data sources may carry additional risk of systematic bias due to data-related differences 244 between data sources. Indeed, large variations have been seen between different types of data such as electronic health records and claims data sources even when using harmonized type of analysis 245 246 and outcome definitions (8). Using rates from randomised trials or spontaneous reporting data may 247 induce even greater variability, related to the specific data collection mechanisms for these 248 activities. Overall, external rates from various sources will continue to be one important source of 249 comparator and contextual information for spontaneous adverse event reporting and estimates of 250 outcome rates in vaccinated groups of people (21-23). But this should not be considered sufficient. 251 Formal studies with contemporaneous comparators, in different databases and using appropriate 252 carefully tuned epidemiological study designs, will be essential components of adverse event 253 monitoring efforts. Fortunately, we are increasingly in a position to do this, as illustrated by the 254 SCIFI-PEARL study initiative (9) and other large-scale register data initiatives.

255 A limitation of this observational study in common with most, is that all outcomes may be subject to 256 measurement error. As all outcome definitions are based on the presence of specific ICD-10 codes 257 and were not further validated, they may lack in sensitivity or specificity, which may affect the estimated incidence rates. However, as a reflection of actual healthcare encounters in the Swedish 258 259 healthcare system, many of these codes and algorithms have been shown to have good validity (10, 260 24). Interestingly, the existence of different patterns of misclassification in different datasets is in 261 fact a strong argument to use the same data source, population and time period for both groups 262 compared when conducting AESI evaluation. The analysis relied on data from 2020 using a target 263 population that was a defined random sample of the total Swedish population on 1 Jan 2020. This 264 provides our analysis with a good level of generalizability. We did not exclude individuals with 265 previous events of the same kind as the AESIs. This design choice is aligned with real-life concerns 266 where AESIs will be an issue whether they occur in people with or without underlying or pre-existing conditions. For many conditions, rates of events are generally somewhat higher in individuals with 267 268 underlying comorbidity of the same type, but in most cases this difference is not very large and the 269 group with underlying comorbidity is a small minority of the total population, so that rates 270 estimated after excluding them will often only be marginally lower than rates estimated from the 271 total population. When using background incidence rates for comparison with rates in vaccinated 272 individuals it is also important to recognize that some AESIs may overlap with symptoms of the infection targeted by the vaccines (in this case COVID-19), which will complicate the comparisons, 273 274 since the rate of infection and/or infection-related symptoms will be lower in the vaccinated 275 individuals if the vaccine is efficacious. Finally, in this study we have estimated incidence rates in 276 sub-categories of age, sex and time periods, and random variation due to small numbers should be 277 considered when interpreting the results. Nevertheless, our study overall is large and we present 278 rates "as observed" i.e. descriptively, which incorporates actual random variation in the underlying 279 data and diseases.

280 In summary, this study, which is based on high-quality Swedish healthcare register data,

281 demonstrates that there is a large variation in estimated AESI incidence rates by age and sex, as well

282 as time period in the Swedish population during 2020. While baseline rates continue to be a vital

reference point and analytic tool for Covid-19 vaccine monitoring (22), these results emphasize the 283

- 284 need for well-designed analytical studies with attention to stratification, standardization or
- 285 adjustment for age, sex and time period. These background rates provide useful real-world clinical

- 8
- 286 context for activities aiming at vaccine monitoring and ensuring patient safety as Covid-19 vaccines
- 287 are applied to combat the pandemic worldwide.
- 288

289 **Tables & Figures**

- 290 Table 1. Age and sex distribution of the sampled Swedish population
- 291 Table 2. Age- and sex-stratified incidence rates of 14 adverse events of special interest (AESIs) per 292 100,000 person-years (with 95% confidence intervals) in the Swedish population
- 293 Figure 1: Age- and sex-stratified incidence rates of 14 adverse events of special interest (AESIs) per 294 100,000 person-years (with 95% confidence intervals) in the Swedish population
- 295 Figure 2: Incidence rates of 14 adverse events of special interest (AESIs) per 100,000 person-years
- 296 (with 95% confidence intervals) in the Swedish population, by guarter of the year 2020
- 297

298 **Declaration of Competing Interests**

- 299 Dr. Nyberg reports prior employment at AstraZeneca until 2019, and ownership of some
- 300 AstraZeneca shares. Dr. Vanfleteren reports grants and personal fees from AstraZeneca, personal
- 301 fees from Novartis, GSK, Chiesi, Menarini, Pulmonx, Resmed, Boehringer, Verona Pharma, AGA Linde
- 302 AstraZeneca (DSMB) outside the submitted work. Dr. Sundström reports ownership in companies
- 303 providing services to Itrim, Amgen, Janssen, Novo Nordisk, Eli Lilly, Boehringer, Bayer, Pfizer and
- 304 AstraZeneca, outside the submitted work. Dr. Gisslen reports personal fees (DSMB) from
- 305 AstraZeneca, personal fees from Gilead, personal fees from GSK/ViiV, personal fees from MSD, other
- from Gilead, other from GSK/ViiV, personal fees from Biogen, personal fees from Novocure, personal 306
- 307 fees from Amgen, personal fees from Novo Nordisk, outside the submitted work.
- 308 Dr. Lindh, Dr. Santosa, Dr. Wettermark, Dr. Hammar and Mr Kirui have nothing to disclose.
- 309

310 Funding

- This vaccination research has received funding from Knut och Alice Wallenbergs Stiftelse / SciLifeLab 311
- 312 (KAW 2021.0010), and the Swedish Research Council (2021-05045, 2021-05450). The underlying
- 313 SCIFI-PEARL study is currently financed by a grants from the Swedish state under the agreement
- 314 between the Swedish government and the county councils, the ALF-agreement (Avtal om
- 315 Läkarutbildning och Forskning / Medical Training and Research Agreement) grant ALFGBG-938453
- 316 and from FORMAS (Forskningsrådet för miljö, areella näringar och samhällsbyggande / Research
- 317 Council for Environment, Agricultural Sciences and Spatial Planning), a government research council
- 318 for sustainable development, grant 2020-02828.
- 319

320 **Supplementary Materials**

321 Supplementary Table 1: Study population by age and sex, numbers and sampling fractions from

- 322 Swedish total population
- 323 Supplementary Table 2. Definitions of adverse events of interest (AESIs)

medRxiv preprint doi: https://doi.org/10.1101/2021.10.04.21263507; this version posted October 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

324

325 Acknowledgements

- 326 We acknowledge Jonatan Nåtman for statistical analysis support.
- 327

328 References

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
 coronavirus in Wuhan, China. The Lancet. 2020;395 (10223):497–506. doi:10.1016/S0140 6736(20)30183-5.

World Health Organization. Coronavirus disease (Covid-19) Weekly Epidemiological
 Update 5 January 2020. Available from: https://www.who.int/emergencies/diseases/novel coronavirus-2019/situation-reports/. Accessed 6 January 2021.

335 3. Ludvigsson JF. The first eight months of Sweden's COVID-19 strategy and the key 336 actions and actors that were involved. Acta Paediatr. 2020 Dec;109(12):2459-2471. doi:

337 10.1111/apa.15582. Epub 2020 Oct 11..

Tegnell A. The Swedish public health response to COVID-19. APMIS. 2021
 Jul;129(7):320-323. doi: 10.1111/apm.13112.

3405.ACCESS: Background rates of Adverse Events of Special Interest for monitoring COVID-34119 vaccines. 2020. http://www.encepp.eu/encepp/viewResource.htm?id=37274 (accessed 13 Sept3422021).

Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology.
 CBER Surveillance Program Background Rates of Adverse Events of Special Interest for COVID-19

345 Vaccine Safety Monitoring Protocol. <u>https://www.bestinitiative.org/wp-</u>

346 <u>content/uploads/2021/02/C19-Vaccine-Safety-AESI-Background-Rate-Protocol-FINAL-2020.pdf</u>
 347 (accessed 13 Sept 2021).

Report of CIOMS Working Group on Vaccine Safety. CIOMS Guide to Active Vaccine
 Safety Surveillance. https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS 20170202-protected.pdf (accessed March 11, 2021).

Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, Martinez-Hernandez E,
 Delmestri A, Verhamme K, Rijnbeek PR, Duarte-Salles T, Suchard M, Ryan P, Hripcsak G, Prieto Alhambra D. Characterising the background incidence rates of adverse events of special interest for
 covid-19 vaccines in eight countries: multinational network cohort study BMJ 2021; 373 :n1435
 doi:10.1136/bmj.n1435.

Nyberg F, Franzén S, Lindh M, Vanfleteren L, Hammar N, Wettermark B, Sundström J,
 Santosa A, Björck S, Gisslén M. Swedish Covid-19 Investigation for Future Insights - A Population
 Epidemiology Approach Using Register Linkage (SCIFI-PEARL). Clin Epidemiol. 2021;13:649-659. doi:
 10.2147/CLEP.S312742.

Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M,
 Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public
 Health. 2011 Jun 9;11:450. doi: 10.1186/1471-2458-11-450.

363 364 365	11.Brighton Collaboration. Priority list of adverse events of special interest: COVID-19.2021. https://brightoncollaboration.us/covid-19/ ; https://brightoncollaboration.us/covid-19/ ; https://brightoncollaboration.us/covid-19/ ; https://brightoncollaboration.us/wp-content/uploads/2021/01/COVID-19-updated-AESI-list.pdf (accessed 14 Sept, 2021).
366 367 368	12. The Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical-Safety Information on Drugs Second Edition – Report of CIOMS Working Groups III and V. Geneva, 1999.
369 370	13. R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
371 372 373	14. Leentjens J, van Haaps TF, Wessels PF, Schutgens REG, Middeldorp S. COVID-19- associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol. 2021 Jul;8(7):e524-e533. doi: 10.1016/S2352-3026(21)00105-8. Epub 2021 Apr 27.
374 375	15. Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ 2021; 372: n699.
376 377 378 379	 16. Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2021 Apr 17;397(10283):1441-1443. doi: 10.1016/S0140-6736(21)00762-5. Epub 2021 Mar 30.
380 381 382	17. Marcucci R, Marietta M. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Intern Emerg Med. 2021 Aug;16(5):1113-1119. doi: 10.1007/s11739-021-02793-x. Epub 2021 Jun 30.
383 384 385 386	18. European Medicines Agency. EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome. News 07/06/2021. https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia. (accessed 14 Sept, 2021).
387 388 389 390	19. European Medicines Agency. Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis. News 09/07/2021. https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases- myocarditis-pericarditis. (accessed 14 Sept, 2021).
391 392 393 394	20. Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, Romano SD, Gundlapalli AV, Oster ME, Harris AM. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 3;70(35):1228-1232. doi: 10.15585/mmwr.mm7035e5.
395 396 397	21. Black S, Eskola J, Siegrist C-A, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374: 2115–22.
398 399 400	22. Rasmussen TA, Jørgensen MRS, Bjerrum S, et al. Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ 2012; 345: e5823.
401	

- 404 24. Friberg L, Skeppholm M. Usefulness of Health Registers for detection of bleeding
- events in outcome studies. Thromb Haemost 2016; 116(06): 1131-1139. DOI: 10.1160/TH16-05-405 0400. 406

Table 1. Age and sex distribution of the sampled Swedish population

	Men	Women	Total
n	480322	492401	972723
n weighted*	489377.5	483345.6	972723.1
person-years	472663.8	484813.3	957477.0
person-years weighted*	487099.8	481010.4	968110.2
Age group, weighted n (%)*			
0-5 years	35200.3 (7.2)	33206.4 (6.9)	
6-17 years	70503.7 (14.4)	66464.8 (13.8)	
18-35 years	117151.5 (23.9)	108807.4 (22.5)	
36-55 years	126170.4 (25.8)	121726.6 (25.2)	
56-64 years	49777.7 (10.2)	49183.9 (10.2)	
65-74 years	50908.0 (10.4)	52741.1 (10.9)	
75-84 years	30783.2 (6.3)	35302.8 (7.3)	
85+ years	8882.7 (1.8)	15912.6 (3.3)	


* Sample weighted to the age/sex structure of the Swedish population

Table 2: Age- and sex-stratified incidence rates per 100,00 person-years (with 95% confidence intervals), colour-coded by CIOMS frequency classification*

						Age groups, years				
	sex	0-5	6-17	18-35	36-55	56-64	65-74	75-84	85+	total
arthritis (all types)	Female	186.4 (137.2, 235.6)	244.8 (205.4, 284.2)	378.1 (337.4, 418.8)	790.9 (735.8, 846.0)	1428.2 (1317.2, 1539.1)	1937.9 (1815.8, 2060.0)	2204.0 (2071.0, 2337.1)	1145.7 (1051.1, 1240.3)	<mark>886.3 (859.3,</mark>
rthritis (all types)	Male	247.1 (190.5, 303.7)	159.8 (127.9 <i>,</i> 191.8)	151.7 (125.9, 177.5)	385.6 (347.1, 424.0)	739.4 (659.7, 819.2)	998.2 (910.4, 1086.1)	1279.2 (1176.1, 1382.2)	804.1 (719.4, 888.8)	<mark>450.6 (431.4,</mark>
Avecatchialringfarctiontps://doi.org/10.1101/2021.1	10.59.29.20.00		o&P9,2621096 & P0,000	_{ନିଧାନି} ଙ୍କ (ରୁ.ଜୁନ୍ଲୁ୦, 5.34)	27.3 (17.0, 37.6)	125.7 (92.8, 158.6)	336.3 (285.2 <i>,</i> 387.4)	704.2 (630.1, 778.3)	1299.7 (1205.3, 1394.2)	<mark>151.1 (141.7,</mark>
Apreprint (which was not certified by peer review)	is the autho	"(tupper (v).868, g.3069) "	1818669 (6:0000, to .650)	the 18 (2.11, 14.2)	118.6 (97.2 <i>,</i> 139.9)	478.0 (414.1, 541.9)	723.3 (648.6, 798.1)	1161.6 (1064.0, 1259.2)	1875.9 (1752.4, 1999.4)	<mark>263.5 (250.2,</mark>
troke It is made available	urenna lec-	B10.12 (0.000, 12ter 6) tiona	9 .84 (1.96 <i>,</i> 17.7)	18.3 (9.31, 27.3)	72.5 (55.7, 89.2)	247.8 (201.5, 294.1)	480.0 (419.0 <i>,</i> 540.9)	1143.0 (1049.2, 1236.9)	2172.7 (2050.7, 2294.8)	<mark>257.0 (244.7,</mark>
troke	Male	23.7 (6.14, 41.2)	8.29 (1.02, 15.6)	27.9 (16.9, 38.8)	121.6 (99.9 <i>,</i> 143.2)	389.7 (331.9 <i>,</i> 447.6)	865.1 (783.2 <i>,</i> 947.0)	1776.5 (1658.2, 1894.7)	2824.3 (2671.6, 2977.0)	<mark>333.6 (319.0,</mark>
schemic stroke	Female	3.38 (0.000, 10.0)	6.52 (0.128, 12.9)	5.16 (0.624, 9.69)	45.4 (32.1, 58.6)	180.5 (141.0, 220.1)	356.6 (304.0 <i>,</i> 409.2)	901.5 (817.8 <i>,</i> 985.2)	1772.0 (1661.5, 1882.5)	<mark>195.2 (184.6,</mark>
schemic stroke	Male	6.76 (0.000, 16.1)	3.25 (0.000, 7.76)	18.4 (9.38, 27.5)	86.3 (68.1, 104.5)	310.8 (259.2, 362.4)	654.5 (583.3 <i>,</i> 725.8)	1368.1 (1263.7, 1472.5)	2097.7 (1965.6, 2229.8)	<mark>251.5 (238.8</mark> ,
cute kidney injury	Female	3.38 (0.000, 10.0)	1.61 (0.000, 4.75)	17.9 (9.08, 26.7)	40.4 (27.9, 52.9)	92.3 (64.0 <i>,</i> 120.5)	259.5 (214.6, 304.4)	707.0 (632.8, 781.2)	1306.3 (1211.5, 1401.1)	<mark>147.0 (137.7,</mark>
cute kidney injury	Male	20.3 (4.06, 36.5)	4.96 (0.000, 10.6)	15.4 (7.29, 23.5)	74.3 (57.4, 91.3)	292.1 (241.9, 342.3)	531.5 (467.3 <i>,</i> 595.7)	1163.6 (1067.8, 1259.4)	2239.9 (2105.0, 2374.8)	223.9 (212.1,
ulmonary embolism	Female	0.000 (0.000, 0.000)	9.63 (1.93, 17.3)	46.6 (32.4, 60.8)	72.0 (55.4, 88.7)	178.1 (138.8, 217.3)	341.9 (290.5, 393.4)	619.7 (549.7 <i>,</i> 689.8)	657.2 (587.6, 726.7)	<mark>152.3 (141.9,</mark>
ulmonary embolism	Male	0.000 (0.000, 0.000)	3.25 (0.000, 7.76)	22.7 (12.7, 32.7)	92.0 (73.2, 110.8)	271.2 (222.9, 319.5)	413.2 (356.6, 469.8)	579.4 (510.3 <i>,</i> 648.5)	667.1 (592.2, 742.1)	<mark>148.8 (138.3,</mark>
ppendicitis	Female	16.9 (2.09, 31.8)	165.6 (133.2, 198.0)	168.2 (141.4, 195.0)	136.6 (113.7, 159.4)	93.3 (64.7, 121.8)	65.9 (43.4 <i>,</i> 88.4)	71.9 (47.1, 96.7)	51.1 (31.0, 71.2)	119.8 (109.4,
ppendicitis	Male	40.6 (17.6, 63.5)	207.8 (171.2, 244.3)	190.4 (161.9, 219.0)	108.4 (88.1, 128.7)	107.5 (77.1, 137.9)	98.9 (71.2, 126.6)	80.9 (54.5, 107.3)	56.8 (34.2, 79.4)	133.7 (122.5,
RDS	Female	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.18 (0.000, 5.21)	13.1 (5.96, 20.2)	36.2 (18.4, 53.9)	32.3 (16.4, 48.1)	47.1 (27.6, 66.7)	27.8 (15.0, 40.6)	15.3 (11.9, 18
RDS	Male	3.38 (0.000, 10.0)	0.000 (0.000, 0.000)	10.4 (3.57, 17.1)	36.3 (24.4, 48.1)	78.6 (52.6, 104.7)	108.9 (79.9, 137.9)	103.0 (75.0, 131.1)	48.8 (28.6, 69.1)	38.8 (33.1, 44
aemmorhagic stroke	Female	6.77 (0.000, 16.2)	1.71 (0.000, 5.06)	13.2 (5.38, 21.0)	30.1 (19.3, 40.9)	74.1 (48.8, 99.4)	126.9 (95.6, 158.2)	263.3 (218.3, 308.2)	413.4 (359.6, 467.2)	65.5 (58.9, 72
aemmorhagic stroke	Male	13.5 (0.271, 26.8)	5.04 (0.000, 10.7)	10.6 (4.03, 17.3)	36.3 (24.4, 48.1)	87.6 (60.1, 115.1)	229.3 (187.1, 271.5)	438.8 (380.3, 497.4)	747.0 (668.0, 826.0)	87.5 (80.0, 95
ostinfectious arthritis	Female	6.77 (0.000, 16.2)	6.73 (0.133, 13.3)	10.6 (4.00, 17.2)	14.1 (6.70, 21.5)	22.7 (8.61, 36.7)	18.3 (6.33, 30.2)	18.8 (6.97, 30.7)	28.6 (14.1, 43.0)	13.9 (10.5, 17
ostinfectious arthritis	Male	23.7 (6.14, 41.2)	4.96 (0.000, 10.6)	21.0 (11.5, 30.5)	18.0 (9.67, 26.3)	31.6 (15.0, 48.1)	28.2 (13.4, 42.9)	35.3 (18.0, 52.6)	36.3 (19.0, 53.5)	21.1 (16.8, 25
utoimmune thyroiditis			91.3 (67.4, 115.2)	45.7 (31.3, 60.1)	44.6 (31.6, 57.6)	36.4 (18.6, 54.3)	25.9 (11.8, 40.0)	22.6 (8.46, 36.7)	2.25 (0.000, 6.67)	42.3 (36.1, 48
utoimmune thyroiditis	Male		23.0 (11.0, 35.1)	8.12 (2.09, 14.1)	10.9 (4.45, 17.3)	6.65 (0.000, 14.2)	6.10 (0.000, 13.0)	10.7 (1.08, 20.4)	3.75 (0.000, 9.26)	10.1 (7.06, 13
enous thromboembolism	Female	0.000 (0.000, 0.000)	3.21 (0.000, 7.66)	11.8 (4.46, 19.1)	22.9 (13.5, 32.3)	47.6 (27.3, 68.0)	44.5 (25.9, 63.1)	88.4 (61.2, 115.5)	54.7 (35.0, 74.3)	26.8 (22.2, 31
enous thromboembolism	Male	0.000 (0.000, 0.000)	4.88 (0.000, 10.4)	11.7 (4.43, 19.0)	27.9 (17.6, 38.3)	38.4 (20.1, 56.6)	54.6 (34.0, 75.2)	78.4 (53.0, 103.7)	59.0 (36.5, 81.6)	26.3 (21.6, 30
cute Liver failure	Female	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	1.98 (0.000, 4.74)	7.13 (1.85, 12.4)	18.0 (5.52, 30.5)	42.2 (24.1, 60.3)	46.4 (27.1, 65.6)	22.2 (9.03, 35.3)	12.8 (9.66, 1
cute Liver failure	Male	3.38 (0.000, 10.0)	0.000 (0.000, 0.000)	5.73 (0.698, 10.8)	12.0 (5.20, 18.8)	35.9 (18.3, 53.5)	68.5 (45.5, 91.5)	96.2 (67.6, 124.8)	78.2 (51.7, 104.7)	23.0 (18.8, 27
yocarditis	Female	3.38 (0.000, 10.0)	8.03 (0.992, 15.1)	9.12 (2.77, 15.5)	6.03 (1.20, 10.9)	6.54 (0.000, 14.0)	4.16 (0.000, 9.92)	11.5 (2.14, 20.8)	6.21 (1.24, 11.2)	7.07 (4.59, 9.
lyocarditis	Male	0.000 (0.000, 0.000)	11.4 (2.95, 19.8)	33.1 (21.4, 44.7)	21.9 (12.7, 31.0)	24.8 (10.1, 39.4)	20.2 (7.68, 32.7)	20.5 (7.41, 33.5)	27.6 (12.3, 42.8)	21.6 (17.2, 20
ebrile seizure	Female	261.1 (202.8, 319.3)	3.42 (0.000, 8.15)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	1.66 (0.000, 4.92)	0.000 (0.000, 0.000)	18.5 (14.5, 22
ebrile seizure	Male	267.5 (208.6, 326.4)	· · · · ·	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)		0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	20.2 (15.9, 24
septic meningitis		0.000 (0.000, 0.000)	- Contract of the second se	11.0 (4.15, 17.9)	0.971 (0.000, 2.88)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.94 (1.27, 4.
septic meningitis	Male	6.76 (0.000, 16.1)	3.42 (0.000, 8.15)	4.56 (0.081, 9.05)	7.01 (1.82, 12.2)	2.32 (0.000, 6.87)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	4.11 (2.09, 6.
rythema multiforme		0.000 (0.000, 0.000)		5.40 (0.643, 10.2)	1.99 (0.000, 4.75)	6.96 (0.000, 14.8)	12.1 (2.42, 21.8)	9.05 (1.01, 17.1)	1.03 (0.000, 3.06)	4.45 (2.51, 6.
rythema multiforme	Male	6.76 (0.000, 16.1)	6.67 (0.132, 13.2)	3.04 (0.000, 6.47)	2.93 (0.000, 6.24)	4.49 (0.000, 10.7)	8.00 (0.161, 15.8)	9.73 (0.932, 18.5)	3.75 (0.000, 9.26)	4.90 (2.87, 6.
awasaki's syndrome			4.92 (0.000, 10.5)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)		0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	2.07 (0.718, 3
awasaki's syndrome		23.7 (6.14, 41.2)	8.37 (1.03, 15.7)	2.02 (0.000, 4.83)		0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	3.39 (1.62, 5.
lisc		0.000 (0.000, 0.000)		0.000 (0.000, 0.000)	0.000 (0.000, 0.000)		0.000 (0.000, 0.000)	1.66 (0.000, 4.92)	0.000 (0.000, 0.000)	1.03 (0.108, 1
lisc	Male	3.38 (0.000, 10.0)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)	0.000 (0.000, 0.000)		2.00 (0.000, 5.92)	2.55 (0.000, 7.55)	0.000 (0.000, 0.000)	0.848 (0.007,
isseminated intravascular coagulation		0.000 (0.000, 0.000)		1.19 (0.000, 3.51)		0.000 (0.000, 0.000)	3.93 (0.000, 9.39)	0.000 (0.000, 0.000)	1.03 (0.000, 3.06)	1.19 (0.170, 2
isseminated intravascular coagulation	Male	0.000 (0.000, 0.000)		1.22 (0.000, 3.63)	0.000 (0.000, 0.000)		2.05 (0.000, 6.06)	1.54 (0.000, 4.57)	0.000 (0.000, 0.000)	1.07 (0.090, 2

* CIOMS: Council of International Organizations of Medical Sciences

CIOMS Frequency classification					
Very rare: <1/10,000					
Rare: >1/10,000 AND <1/1,000					
Uncommon: >1/1,000 AND <1/100					
Common: >1/100 AND <1/10					
Very common: >1/10					



Female Male

